HealthcareServices

Cardiac Tissue Engineering Market Insights Report: Opportunities and Drivers 2030

February 20, 2026February 23, 2026 by Marketing Posting

Uncover key drivers, emerging technologies, and competitive movements shaping the cardiac tissue engineering market from 2026–2035 with trusted insights from The Business Research Company

By how much is the Cardiac Tissue Engineering Market expected to grow between 2026 and 2030?

The cardiac tissue engineering market size has seen swift expansion in recent years. It is anticipated to increase from $0.8 billion in 2025 to $0.96 billion in 2026, exhibiting a compound annual growth rate (CAGR) of 19.4%. The historical rise in this market can be ascribed to advancements in stem cell research, a greater prevalence of cardiovascular diseases, the expansion of translational cardiac research programs, the availability of advanced biomaterials, and an increase in academic-industry collaborations.

The cardiac tissue engineering market size is anticipated to undergo significant growth in the upcoming years. It is projected to expand to $1.92 billion by 2030, exhibiting a compound annual growth rate (CAGR) of 19.0%. This expansion over the forecast period is attributable to increasing investment in regenerative medicine, a rising need for alternatives to donor tissues, the broadening of personalized cardiac therapies, the expanding clinical translation of engineered tissues, and advancements in biofabrication techniques. Prominent trends for the forecast period involve the increasing development of tissue-engineered heart valves, a rising utilization of stem cell-based cardiac therapies, the growing adoption of advanced biomaterial scaffolds, the expansion of regenerative approaches for myocardial repair, and an enhanced focus on functional tissue maturation.

Access Your Free Sample Report for In-Depth Market Insights:

https://www.thebusinessresearchcompany.com/sample.aspx?id=21129&type=smp

Which Drivers Are Influencing Market Acceleration In The Cardiac Tissue Engineering Market?

An increasing occurrence of cardiovascular diseases is anticipated to fuel the expansion of the cardiac tissue engineering market in the future. This interdisciplinary field focuses on developing biological or bioartificial constructs to mend, restore, or substitute impaired heart tissue. The growing prevalence of cardiovascular conditions largely stems from detrimental lifestyle habits such as inadequate nutrition, lack of physical activity, smoking, and rising levels of obesity and diabetes. Cardiac tissue engineering addresses cardiovascular diseases by creating biomaterials, cell-based treatments, and bioengineered tissues to repair or regenerate compromised heart muscle and reinstate heart function. For example, in May 2023, the Centers for Disease Control and Prevention, a US-based governmental body, reported that the proportion of coronary heart disease in female adults aged 18 and over saw a slight rise from 3.6% in 2022 to 3.7% in 2023. Thus, the escalating incidence of cardiovascular diseases is propelling the growth of the cardiac tissue engineering market.

What Segments Are Identified Within The Structure Of The Cardiac Tissue Engineering Market?

The cardiac tissue engineering market covered in this report is segmented –

1) By Product: Heart Valves, Vascular Grafts

2) By Material: Stem Cells, Scaffolds

3) By Application: Myocardial Infarction, Heart Valve Repair Or Replacement, Congenital Heart Disease Treatment, Other Applications

4) By End Users: Hospitals And Clinics, Academic And Research Institutes, Other End Users

Subsegments:

1) By Heart Valves: Bioprosthetic Heart Valves, Tissue-Engineered Heart Valves

2) By Vascular Grafts: Biologic Vascular Grafts, Tissue-Engineered Vascular Grafts

Which Major Firms Are Strengthening Their Position In The Cardiac Tissue Engineering Market?

Major companies operating in the cardiac tissue engineering market are Xeltis AG, Humacyte Inc., Carmat S.A., Artivion Inc., Tissue Regenix Group plc, Cytograft Tissue Engineering Inc., BioCardia Inc., Bioheart Inc., Cardio3 Biosciences, Osiris Therapeutics Inc., StemCells Inc., CorMatrix Cardiovascular Inc., Vascugen Inc., CellProthera S.A., Myocardial Solutions Inc., Vericel Corporation, Lineage Cell Therapeutics Inc., Pluristem Therapeutics Inc., Reva Medical Inc., SynCardia Systems Inc.

Access The Complete Report For Deeper Market Insights:

https://www.thebusinessresearchcompany.com/report/cardiac-tissue-engineering-global-market-report

Which Region Is Anticipated To See The Fastest Growth In The Cardiac Tissue Engineering Market?

North America was the largest region in the cardiac tissue engineering market in 2025. The regions covered in the cardiac tissue engineering market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.

Request Your Customized Cardiac Tissue Engineering Market Research Report for Competitive Advantage:

https://www.thebusinessresearchcompany.com/customise?id=21129&type=smp

Browse Through More Reports Similar to the Global Cardiac Tissue Engineering Market 2026, By The Business Research Company

Cardiac Prosthetic Devices Market Report 2026

https://www.thebusinessresearchcompany.com/report/cardiac-prosthetic-devices-global-market-report

Cardiovascular Implants Market Report 2026

https://www.thebusinessresearchcompany.com/report/cardiovascular-implants-global-market-report

Medical Engineered Materials Market Report 2026

https://www.thebusinessresearchcompany.com/report/medical-engineered-materials-global-market-report

Get in touch with us:

The Business Research Company: https://www.thebusinessresearchcompany.com/

Americas +1 310-496-7795